» Articles » PMID: 36471194

Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives

Overview
Publisher Springer
Specialty General Medicine
Date 2022 Dec 5
PMID 36471194
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Primary care providers (PCPs) are essential to increasing access to office-based buprenorphine medication treatment for opioid use disorder (B-MOUD). Barriers to B-MOUD prescribing are well-documented, but there is little information regarding incentives to overcome these barriers.

Objective: To identify optimal incentives for PCPs to promote B-MOUD prescribing and compare incentive preferences across provider and practice characteristics.

Design: We surveyed PCPs using best-worst scaling (BWS) to prioritize seven potential incentives for B-MOUD prescribing (monetary compensation, paid vacation, protected time, professional development, reduced workload, service recognition, clinical resources). We then used a direct elicitation approach to determine preferred incentive levels (e.g., monetary thresholds) and types (e.g., specific clinical resources).

Participants: Primary care physicians and advanced practice providers (APPs) at a large Department of Veterans Affairs healthcare system.

Main Measures: B-MOUD prescribing incentive preferences and relative preference levels using descriptive statistics and conditional logistic regression with relative importance scale transformation (coefficients sum to 100, higher coefficient=greater importance).

Key Results: Fifty-three PCPs responded (73% response), including 47% APPs and 36% from community-based clinics. Reduced workload (relative importance score=26.8), protected time (18.7), and clinical resources (16.8) were significantly more preferred (Ps < 0.001) than professional development (10.5), paid vacation (10.3), or service recognition (1.5). Relative importance of monetary compensation varied between physicians (12.6) and APPs (17.5) and between PCPs located at a medical center (11.4) versus community clinic (22.3). APPs were more responsive than physicians to compensation increases of $5000 and $12,000 but less responsive to $25,000; trends were similar for medical center versus community clinic PCPs. The most frequently requested clinical resource was on-demand consult access to an addiction specialist.

Conclusions: Interventions promoting workload reductions, protected time, and clinical resources could increase access to B-MOUD in primary care. Monetary incentives may be additionally needed to improve B-MOUD prescribing among APPs and within community clinics.

Citing Articles

Evaluation of a Program Designed to Support Implementation of Prescribing Medication for Treatment of Opioid Use Disorder in Primary Care Practices.

Hall T, Mendez D, Sobczak C, Mathieu S, Wiggins K, Cebuhar K Ann Fam Med. 2025; 23(1):44-51.

PMID: 39805692 PMC: 11772038. DOI: 10.1370/afm.3190.


Hospital Provider's Perspectives on MOUD Initiation and Continuation After Inpatient Discharge.

Shearer R, Englander H, Hagedorn H, Fawole A, Laes J, Titus H J Gen Intern Med. 2024; .

PMID: 39586949 DOI: 10.1007/s11606-024-09008-x.


Optimizing Patient Engagement in Treatment for Opioid Use Disorder: Primary Care Team Perspectives on Influencing Factors.

Austin E, Chen J, Soyer E, Idrisov B, Briggs E, Ferro L J Gen Intern Med. 2024; 39(16):3196-3204.

PMID: 39073482 PMC: 11618257. DOI: 10.1007/s11606-024-08963-9.


Integrating Buprenorphine for Opioid Use Disorder into Rural, Primary Care Settings.

Wyse J, Eckhardt A, Newell S, Gordon A, Morasco B, Carlson K J Gen Intern Med. 2024; 39(12):2142-2149.

PMID: 38955895 PMC: 11347530. DOI: 10.1007/s11606-024-08898-1.


Knowledge, Attitudes, and Beliefs About Opioid Use Disorder Treatment in Primary Care.

Del Pozo B, Park J, Taylor B, Wakeman S, Ducharme L, Pollack H JAMA Netw Open. 2024; 7(6):e2419094.

PMID: 38941101 PMC: 11214109. DOI: 10.1001/jamanetworkopen.2024.19094.


References
1.
Kilaru A, Lubitz S, Davis J, Eriksen W, Siegel S, Kelley D . A State Financial Incentive Policy to Improve Emergency Department Treatment for Opioid Use Disorder: A Qualitative Study. Psychiatr Serv. 2021; 72(9):1048-1056. DOI: 10.1176/appi.ps.202000501. View

2.
Wyse J, Gordon A, Dobscha S, Morasco B, Tiffany E, Drexler K . Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Subst Abus. 2018; 39(2):139-144. PMC: 8054831. DOI: 10.1080/08897077.2018.1452327. View

3.
Foti K, Heyward J, Tajanlangit M, Meek K, Jones C, Kolodny A . Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey. Drug Alcohol Depend. 2021; 225:108811. PMC: 10659122. DOI: 10.1016/j.drugalcdep.2021.108811. View

4.
Kelley A, Dungan M, Gordon A . Barriers and Facilitators to Buprenorphine Prescribing for Opioid Use Disorder in the Veterans Health Administration During COVID-19. J Addict Med. 2020; 15(5):439-440. PMC: 8489586. DOI: 10.1097/ADM.0000000000000786. View

5.
Kelley A, Incze M, Baylis J, Calder S, Weiner S, Zickmund S . Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice. Subst Abus. 2022; 43(1):1286-1299. PMC: 9703846. DOI: 10.1080/08897077.2022.2095082. View